280 related articles for article (PubMed ID: 31055231)
21. Inhibition of the JNK signaling pathway increases sensitivity of hepatocellular carcinoma cells to cisplatin by down-regulating expression of P-glycoprotein.
Liu XY; Liu SP; Jiang J; Zhang X; Zhang T
Eur Rev Med Pharmacol Sci; 2016; 20(6):1098-108. PubMed ID: 27049263
[TBL] [Abstract][Full Text] [Related]
22. Synergism of cisplatin-oleanolic acid co-loaded calcium carbonate nanoparticles on hepatocellular carcinoma cells for enhanced apoptosis and reduced hepatotoxicity.
Khan MW; Zhao P; Khan A; Raza F; Raza SM; Sarfraz M; Chen Y; Li M; Yang T; Ma X; Xiang G
Int J Nanomedicine; 2019; 14():3753-3771. PubMed ID: 31239661
[No Abstract] [Full Text] [Related]
23. Pyrrolidine dithiocarbamate reverses Bcl-xL-mediated apoptotic resistance to doxorubicin by inducing paraptosis.
Park SS; Lee DM; Lim JH; Lee D; Park SJ; Kim HM; Sohn S; Yoon G; Eom YW; Jeong SY; Choi EK; Choi KS
Carcinogenesis; 2018 Mar; 39(3):458-470. PubMed ID: 29329420
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of localized ultrasound-targeted microbubble destruction with doxorubicin liposomes in H22 mouse hepatocellular carcinoma model.
Zhu F; Jiang Y; Luo F; Li P
J Drug Target; 2015 May; 23(4):323-34. PubMed ID: 25609362
[TBL] [Abstract][Full Text] [Related]
25. EGFR-targeted multifunctional polymersomal doxorubicin induces selective and potent suppression of orthotopic human liver cancer in vivo.
Fang Y; Yang W; Cheng L; Meng F; Zhang J; Zhong Z
Acta Biomater; 2017 Dec; 64():323-333. PubMed ID: 29030307
[TBL] [Abstract][Full Text] [Related]
26. Polydatin Inhibits Hepatocellular Carcinoma Cell Proliferation and Sensitizes Doxorubicin and Cisplatin through Targeting Cell Mitotic Machinery.
Farooq U; Wang H; Hu J; Li G; Jehan S; Shi J; Li D; Sui G
Cells; 2023 Jan; 12(2):. PubMed ID: 36672157
[TBL] [Abstract][Full Text] [Related]
27. The effect of doxorubicin on MEK-ERK signaling predicts its efficacy in HCC.
Choi J; Yip-Schneider M; Albertin F; Wiesenauer C; Wang Y; Schmidt CM
J Surg Res; 2008 Dec; 150(2):219-26. PubMed ID: 18468633
[TBL] [Abstract][Full Text] [Related]
28. GRP78-targeted ferritin nanocaged ultra-high dose of doxorubicin for hepatocellular carcinoma therapy.
Jiang B; Zhang R; Zhang J; Hou Y; Chen X; Zhou M; Tian X; Hao C; Fan K; Yan X
Theranostics; 2019; 9(8):2167-2182. PubMed ID: 31149036
[TBL] [Abstract][Full Text] [Related]
29. Expression of TNF-related apoptosis-inducing Ligand receptors and antitumor tumor effects of TNF-related apoptosis-inducing Ligand in human hepatocellular carcinoma.
Chen XP; He SQ; Wang HP; Zhao YZ; Zhang WG
World J Gastroenterol; 2003 Nov; 9(11):2433-40. PubMed ID: 14606071
[TBL] [Abstract][Full Text] [Related]
30. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma.
Chen X; Ding G; Gao Q; Sun J; Zhang Q; Du L; Qiu Z; Wang C; Zheng F; Sun B; Ni J; Feng Z; Zhu J
PLoS One; 2013; 8(5):e63093. PubMed ID: 23675455
[TBL] [Abstract][Full Text] [Related]
31. siRNA Targeting of MDR1 Reverses Multidrug Resistance in a Nude Mouse Model of Doxorubicin-resistant Human Hepatocellular Carcinoma.
Yang H; Ding R; Tong Z; Huang J; Shen L; Sun YU; Liao J; Yang Z; Hoffman RM; Wang C; Meng X
Anticancer Res; 2016 Jun; 36(6):2675-82. PubMed ID: 27272776
[TBL] [Abstract][Full Text] [Related]
32. Low density lipoprotein as a targeted carrier for doxorubicin in nude mice bearing human hepatoma HepG2 cells.
Chu AC; Tsang SY; Lo EH; Fung KP
Life Sci; 2001 Dec; 70(5):591-601. PubMed ID: 11811903
[TBL] [Abstract][Full Text] [Related]
33. Thymoquinone Selectively Induces Hepatocellular Carcinoma Cell Apoptosis in Synergism With Clinical Therapeutics and Dependence of p53 Status.
Jehan S; Zhong C; Li G; Zulqarnain Bakhtiar S; Li D; Sui G
Front Pharmacol; 2020; 11():555283. PubMed ID: 33041795
[TBL] [Abstract][Full Text] [Related]
34. MiR-375 delivered by lipid-coated doxorubicin-calcium carbonate nanoparticles overcomes chemoresistance in hepatocellular carcinoma.
Zhao P; Wu S; Cheng Y; You J; Chen Y; Li M; He C; Zhang X; Yang T; Lu Y; Lee RJ; He X; Xiang G
Nanomedicine; 2017 Nov; 13(8):2507-2516. PubMed ID: 28577837
[TBL] [Abstract][Full Text] [Related]
35. Dendrimer-doxorubicin conjugates exhibit improved anticancer activity and reduce doxorubicin-induced cardiotoxicity in a murine hepatocellular carcinoma model.
Kuruvilla SP; Tiruchinapally G; Crouch AC; ElSayed MEH; Greve JM
PLoS One; 2017; 12(8):e0181944. PubMed ID: 28829785
[TBL] [Abstract][Full Text] [Related]
36. Ellagic acid inhibits human pancreatic cancer growth in Balb c nude mice.
Zhao M; Tang SN; Marsh JL; Shankar S; Srivastava RK
Cancer Lett; 2013 Sep; 337(2):210-7. PubMed ID: 23684930
[TBL] [Abstract][Full Text] [Related]
37. XLF-mediated NHEJ activity in hepatocellular carcinoma therapy resistance.
Yang S; Wang XQ
BMC Cancer; 2017 May; 17(1):344. PubMed ID: 28526069
[TBL] [Abstract][Full Text] [Related]
38. Synergistic growth inhibitory effects of Phyllanthus emblica and Terminalia bellerica extracts with conventional cytotoxic agents: doxorubicin and cisplatin against human hepatocellular carcinoma and lung cancer cells.
Pinmai K; Chunlaratthanabhorn S; Ngamkitidechakul C; Soonthornchareon N; Hahnvajanawong C
World J Gastroenterol; 2008 Mar; 14(10):1491-7. PubMed ID: 18330936
[TBL] [Abstract][Full Text] [Related]
39. All-trans retinoic acid potentiates the chemotherapeutic effect of cisplatin by inducing differentiation of tumor initiating cells in liver cancer.
Zhang Y; Guan DX; Shi J; Gao H; Li JJ; Zhao JS; Qiu L; Liu J; Li N; Guo WX; Xue J; Zhou FG; Wu MC; Wang HY; Xie D; Cheng SQ
J Hepatol; 2013 Dec; 59(6):1255-63. PubMed ID: 23867314
[TBL] [Abstract][Full Text] [Related]
40. Synergistic Effects of Ellagic Acid and Sorafenib on Hepatocytes and Mitochondria Isolated from a Hepatocellular Carcinoma Rat Model.
Salimi A; Saboji M; Seydi E
Nutr Cancer; 2021; 73(11-12):2460-2468. PubMed ID: 33030061
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
